Saturday, 20 July 2019

Oramed submits pre-IND for exenatide to FDA

02 August 2013 | Regulatory | By BioSpectrum Bureau

Oramed submits pre-IND meeting request to FDA for its oral exenatide capsule ORMD-0901

Oramed submits pre-IND meeting request to FDA for its oral exenatide capsule ORMD-0901

Singapore: Oramed Pharmaceuticals, a developer of oral drug delivery systems, submitted a pre-Investigational New Drug (pre-IND) meeting request to the US FDA for a US-based trial on its orally ingestible exenatide capsule, ORMD-0901.

Mr Nadav Kidron, CEO, Oramed, commented that, "We are very pleased to have submitted this pre-IND meeting request letter as part of our efforts to advance ORMD-0901 into US clinical trials. We look forward to the FDA's response and preparing ourselves accordingly in our efforts leading up to full IND submission on our second product."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls